Granite Investment Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Granite Investment Partners’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$399K	Sell	5,026 -319	-6%	-$24K	0.02%	203
2026 Q1	$401K	Buy	5,345 +539	+11%	+$42.5K	0.02%	200
2025 Q4	$380K	Sell	4,806 -23,227	-83%	-$1.75M	0.02%	202
2025 Q3	$1.83M	Sell	28,033 -15,148	-35%	-$740K	0.1%	164
2025 Q2	$1.71M	Sell	43,181 -25,253	-37%	-$826K	0.08%	185
2025 Q1	$2.06M	Sell	68,434 -5,432	-7%	-$178K	0.1%	182
2024 Q4	$2.58M	Sell	73,866 -11,927	-14%	-$446K	0.11%	176
2024 Q3	$3.44M	Sell	85,793 -28,297	-25%	-$1.32M	0.15%	163
2024 Q2	$5.44M	Sell	114,090 -2,054	-2%	-$84.2K	0.23%	138
2024 Q1	$5.03M	Sell	116,144 -3,802	-3%	-$181K	0.19%	149
2023 Q4	$6.07M	Buy	+119,946	New	+$5.75M	0.24%	124

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Granite Investment Partners's IONS Position: Q2 2026 in Review

Granite Investment Partners reduced its Ionis Pharmaceuticals (IONS) stake by 6% in Q2 2026, selling an estimated $24K and leaving 5,026 shares worth $399K. The position accounts for 0.02% of the portfolio, ranked #203.

Granite Investment Partners first reported a position in IONS in Q4 2023 and has held it in 11 quarters since. The position peaked at $6.07M in Q4 2023. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Granite Investment Partners held 5,026 shares of Ionis Pharmaceuticals worth $399K as of Q2 2026.
Granite Investment Partners sold 319 Ionis Pharmaceuticals shares in Q2 2026, an estimated $24K.
Ionis Pharmaceuticals made up 0.02% of Granite Investment Partners's portfolio in Q2 2026, its #203 holding.
Granite Investment Partners first reported a position in Ionis Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Granite Investment Partners's Ionis Pharmaceuticals position peaked at $6.07M in Q4 2023.
515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Granite Investment Partners's 13F filing for Q2 2026, filed 7 Aug 2026.